Figure 2.

Survival analysis according to platelet reactivity. A, Cardiac survival curves demonstrated a long‐term benefit in the OPR group compared with the HPR subgroup in which antiplatelet therapy was “not switched.” Conversely, after a “tailored” antiplatelet therapy by escalation and/or change, no more significant differences in survival curves were detected between the HPR “switched” subgroup and the OPR group. B, Survival analysis including discontinuation time of DAPT as censoring event together with death and loss to follow‐up in OPR and HPR “switched” groups. DAPT indicates dual antiplatelet therapy; HPR, high platelet reactivity; OPR, optimal platelet reactivity.